Her2 DNA vaccine as adjunct treatment for cancers in companion animals
AssigneeMerial Limited
InventorLaurent Bernard Fischer
Life of this patent
Estimating the term…
Abstract
The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines.
Claims11
A method for treating canine mammary carcinoma/tumor in a dog suffering from a canine mammary carcinoma/tumor comprising mammary cells expressing a Her2/neu antigen, comprising:
- a) surgically debulking said tumor;
- and
- b) administering to said dog a clinically-effective amount of a first plasmid comprising a DNA sequence encoding a xenogeneic Her2/neu antigen under the control of a promoter which promotes expression of said Her2/neu antigen in said dog;
- and
- wherein canines receiving said plasmid exhibit significantly increased overall, disease-free, and/or metastasis-free survival times relative to canines receiving said surgical debulking without subsequent administration of said plasmid, thereby treating said carcinoma/tumor.
Dependencies are inferred from the claim text.